Pure Global AI
NCT06289920Recruiting

A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of BR3005 and Co-administration of BR3005-1 and BR3005-2 Under Fasting Conditions in Healthy Adult Volunteers

An Open Label, Randomized, Fasting, Single Dose, 2-sequence, 2-period, Crossover Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of BR3005 and Co-administration of BR3005-1 and BR3005-2 in Healthy Adult Volunteers
Boryung Pharmaceutical Co., LtdPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes Mellitus
Drug/Device/Intervention
BR3005
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Boryung Pharmaceutical Co., Ltd
Location
Seoul, South Korea
Timeline & enrollment
Phase
Phase 1
Start date
Mar 01, 2024
End date
Mar 01, 2024
Enrollment
46 participants
Primary outcome

AUCτ,Cmax

Summary

The objective of this clinical study is to compare the pharmacokinetics and the safety
 between a fixed-dose combination administration of BR3005 and co-administration of
 BR3005-1 and BR3005-2 under fasting conditions in healthy adult volunteers

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06289920
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06289920 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boryung Pharmaceutical Co., Ltd and is currently Recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 46 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.